Drugs / GC5107A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02063789 | Jun 2014 → Apr 2016 | autoimmune thrombocytopenia | Green Cross Corporation | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC5107A | “GC5107A (IV-Globulin SN Inj. 10%) is a polyvalent intravenous human immunoglobulin G preparation.” NCT02063789 ↗ |
| Known as | GC5107A (IV-Globulin SN Inj. 10%) | “GC5107A (IV-Globulin SN Inj. 10%)” NCT02063789 ↗ |
| Modality | Protein / enzyme biologic | “GC5107A (IV-Globulin SN Inj. 10%) is a polyvalent intravenous human immunoglobulin G preparation.” NCT02063789 ↗ |
| Route | Intravenous | “After GC5107A Intravenous injection” NCT02063789 ↗ |